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Abstract
Objective: Myasthenia gravis (MG) is an autoimmune condition in which neu-
rotransmission is impaired by binding of autoantibodies to acetylcholine recep-
tors (AChR) or, in a minority of patients, to muscle specific kinase (MuSK).
There are differences in the dominant IgG subclass, pathogenic mechanisms,
and treatment responses between the two MG subtypes (AChR or MuSK). The
antibodies are thought to be T-cell dependent, but the mechanisms underlying
their production are not well understood. One aspect not previously described
is whether defects in central and peripheral tolerance checkpoints, which allow
autoreactive B cells to accumulate in the naive repertoire, are found in both or
either form of MG. Methods: An established set of assays that measure the fre-
quency of both polyreactive and autoreactive B cell receptors (BCR) in naive
populations was applied to specimens collected from patients with either AChR
or MuSK MG and healthy controls. Radioimmuno- and cell-based assays were
used to measure BCR binding to AChR and MuSK. Results: The frequency of
polyreactive and autoreactive BCRs (n = 262) was higher in both AChR and
MuSK MG patients than in healthy controls. None of the MG-derived BCRs
bound AChR or MuSK. Interpretation: The results indicate that both these
MG subtypes harbor defects in central and peripheral B cell tolerance check-
points. Defective B cell tolerance may represent a fundamental contributor to
autoimmunity in MG and is of particular importance when considering the
durability of myasthenia gravis treatment strategies, particularly biologics that
eliminate B cells.
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Introduction
Myasthenia gravis (MG) is a chronic autoantibody-
mediated disorder of the neuromuscular junction charac-
terized by muscle weakness and fatigability.1 In the
majority of patients the autoantibodies target the acetyl-
choline receptor (AChR),2 while a smaller population is
defined by autoantibodies targeting muscle specific kinase
(MuSK).3 Although the immunopathology is directly
mediated by these autoantibodies, their mechanisms dif-
fer. In AChR MG the autoantibodies are primarily of the
IgG1 subclass4 and lead to the loss of AChR through
internalization and by localized complement-mediated
postsynaptic damage. The majority of autoantibodies that
recognize MuSK are of the IgG4 subclass and do not
cause internalization or fix complement. Instead, MuSK
autoantibodies inhibit the agrin-LRP4-MuSK-AChR clus-
tering pathway by preventing agrin-activated LRP4 bind-
ing to MuSK, leading to dispersal of the AChRs.5,6 The
two subtypes of MG also differ in clinical presentation
and in response to immunotherapies.7 For example, B cell
depletion therapy has shown encouraging results in MuSK
MG but appears less effective in AChR MG.8,9 This obser-
vation suggests that there might be differences in the
underlying B cell populations that give rise to the autoan-
tibodies.
To evade the development of an immune response
against self, two separate tolerance mechanisms counter-
select B cells during their development.10 The first is a
central tolerance checkpoint in the bone marrow between
the early immature and immature B cell development
stages, which removes a large population of B cells that
express self-reactive antibodies.11 The second checkpoint
selects against self-reactive new emigrant/transitional B
cells before they enter the mature naive B cell compart-
ment. Deficiencies in the integrity of these tolerance
mechanisms can be demonstrated through quantifying the
frequency of both polyspecific and autoreactive B cells
downstream of each checkpoint. A number of autoim-
mune diseases include central and peripheral B cell check-
points that fail to enforce tolerance.12–14
Despite the detailed understanding of MG pathophysi-
ology, there are no reports of whether defects in autoim-
mune regulation, namely tolerance, contribute to this
disease. Here we asked whether the naive B cell repertoire
in MG shows evidence of compromised tolerance, due to
checkpoint defects, leading to the accumulation of autore-
active B cells in the naive compartment. Given the diver-
gent immunobiology underlying AChR and MuSK MG,
we included study subjects representing both disease
subtypes to determine whether there are differences in B
cell tolerance integrity between the two forms of the
disease.
Materials and Methods
Study subjects
Patients were recruited from the Yale Myasthenia Gravis
Clinic or the University of Kansas, Department of Neu-
rology. Peripheral blood was obtained from healthy con-
trols and patients with MG after providing informed
consent. Peripheral blood mononuclear cells (PBMC)
were isolated from the blood, aliquoted and cryopreserved
in liquid nitrogen until use. The MG patients were pri-
marily immunotherapy naive (Table 1). All patients had
clinical and electrodiagnostic features consistent with MG
and were tested for either AChR or MuSK autoantibodies
using a commercial radioimmunoassay (RIA) as part of
their clinical evaluation. Collected clinical data included
demographics, duration of disease, immunosuppressive
medications, thymoma/thymectomy status and Myasthe-
nia Gravis Foundation of America (MGFA) Clinical Clas-
sification (Table 1). The healthy controls had no reported
history of autoimmune disease, or malignancies and no
acute or chronic infections. These controls were matched
to the patients as closely as possible with regard to age
and gender (Table 1). Patients and healthy donors were
further clinically assessed for the possibility of co-morbid
autoimmunity; no such co-morbidity was present. Addi-
tionally, serological antibody screening for subclinical
autoimmune disease included measurement of autoanti-
bodies against nuclear antigens (ANA panel) or extracta-
ble nuclear antigens (ENA panel). These tests were
performed, using commercial assays, by the Department
of Laboratory Medicine at Yale New Haven Hospital
(Table 1). Direct sequencing of the PTPN22 R620W poly-
morphism region was performed on all subjects in the
study.15
Study approval
Specimens originating from patients were collected after
informed written consent was obtained under a protocol
approved by the Human Research Protection Program at
Yale School of Medicine.
Cell staining and sorting
Single B cells were isolated as previously described.16
Briefly, peripheral B cells from the MG patients and healthy
controls were isolated by positive selection using CD20
magnetic beads (Miltenyi). Single CD19+CD21loCD10+
IgMhiCD27– new emigrant/transitional and CD19+CD21+
CD10–IgM+CD27– mature naive B cells were sorted on a
FACSAria flow cytometer (BD) into 96-well PCR plates
and immediately frozen on dry ice.
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Recombinant antibody production
Reverse transcription of the RNA and RT-PCR reactions,
primer sequences, cloning strategy, expression vectors, anti-
body expression, and purification were performed as previ-
ously described.11,17 Immunoglobulin sequences were
analyzed using the IgBLAST tool18 on the NCBI website
(http://www.ncbi.nlm.nih.gov/projects/igblast) or the
IMGT/V-QUEST tool available at the International ImMu-
noGeneTics information system (IMGT) website (http://
www.imgt.org).19 Clones were selected for recombinant
expression based on successful amplification of both the
heavy and light chain variable region and sequence fidelity
with the germline variable region gene segments (Table S1).
ELISA
Cell culture supernatants containing recombinant IgG
(rIgG) were tested for polyspecificity using plates coated
with dsDNA, LPS or recombinant human insulin (all
from Sigma) using a previously described approach.11
HEp-2 binding was tested using purified rIgG and a com-
mercially available ELISA kit (INOVA) according to the
manufacturer’s instructions with minor modifications that
were previously described.13
MG autoantigen specificity
Binding to AChR or MuSK was tested using purified rIgG
and a commercial radioimmunoassay (RIA, RSR Ltd).
These results were confirmed by testing for binding to
human embryonic kidney cells transfected with DNAs
encoding MuSK or the four subunits of the adult isoform
of AChR and rapsyn as previously described.20,21
Statistics and graphing
Differences between patient groups and healthy controls
were analyzed for statistical significance with Kruskal-
Wallis tests using Prism software (GraphPad). P-values of
less than 0.05 were considered statistically significant.
Power calculations were performed based on the large and
reproducible effect size derived from the assay in earlier
studies.12–14,16 The 3-D plots of the polyreactivity ELISA
data were analyzed and plotted using the R statistical com-
puting environment and the R package ggplot2.22,23
Results
Study design and approach
To determine whether B cell tolerance is maintained in
MG patients we utilized a well described approach11,24–26
that assesses the fidelity of the two tolerance checkpoints
guiding B cell development. The approach is applied to
measure the frequency of polyreactive and autoreactive B
cell receptors (BCR) in the naive repertoire, which associ-
ates with the extent of negative selection thereby provid-
ing an assessment of the checkpoint integrity. Specifically,
peripheral blood new emigrant/transitional and mature
naive B cells, which are each respectively downstream of
the central and peripheral B cell tolerance checkpoints,
were sorted into single wells. Recombinant antibodies
were generated from each single cell, as a means to repre-
sent their BCR, which were then tested for reactivity
against a panel of defined antigens. The frequency of
BCRs from new emigrant/transitional B cells (metric for
central tolerance integrity) and the frequency of BCRs
from mature naive B cells (metric for peripheral tolerance
integrity) expressing poly- and/or autoreactive antibodies
were determined and compared to healthy controls, where
tolerance is properly established. The approach produces
a large effect size when tolerance is compromised; there-
fore we enrolled five MG patients and two healthy con-
trols. We selected our patients based on their well-defined
diagnosis of MG and the absence of aggressive
immunotherapy that may alter the tolerance assay results.
The MG cohort included two immunotherapy naive gen-
eralized AChR MG patients; one immunotherapy naive
ocular AChR MG patient and two MuSK MG patients
who had received low dose corticosteroids but had not
begun aggressive immunotherapy (Table 1). All patients
and controls were negative for the PTPN22*R620W vari-
ant risk factor allele, which is associated with dysfunc-
tional central tolerance.15 Patients and controls were also
negative for co-morbid autoimmunity; both clinically and
based on ANA and ENA screening (Table 1). A total of
109 new emigrant/transitional and 88 mature naive BCRs
were cloned from the MG cohort (Table S2) along with
33 new emigrant/transitional and 32 mature naive BCRs
from the healthy controls (Table S2). Recombinant anti-
bodies were produced in duplicate from each of these
cloned BCRs, totaling 394 MG and 130 control antibodies
available for the study.
Central tolerance checkpoint fidelity
The central tolerance checkpoint integrity was measured
by determining the frequency of new emigrant/transi-
tional B cells that were characterized as polyreactive
through displaying reactivity toward three structurally dis-
tinct antigens: dsDNA, lipopolysaccharide (LPS) and insu-
lin. The fraction of BCRs that were positive for binding
all three antigens from the healthy controls was compared
to the same fraction found in the three AChR and two
MuSK MG patients (Fig. 1A and Fig. S1). The median
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fraction of polyreactive BCRs in the healthy controls was
8.9%, while in the AChR and MuSK MG patients the
fraction was 23.3% and 51.7% respectively (Fig. 1B).
These values were statistically different (P = 0.029). Col-
lectively, in all five MG patients the mean fraction of
polyreactive BCRs was 36.1%  14.8 and in the two
healthy controls, where central B cell tolerance is estab-
lished normally, the mean fraction of polyreactive BCRs
was 8.9%  3.1. These respective values are in agreement
with previously reported frequencies of polyreactive new
emigrant/transitional BCRs in individuals with autoim-
mune diseases that include well-characterized central tol-
erance abnormalities and in healthy controls.11,24–26 These
results indicate that the B cell central tolerance checkpoint
is dysfunctional in both AChR and MuSK MG patients.
Peripheral tolerance checkpoint fidelity
The peripheral tolerance checkpoint integrity was mea-
sured by first determining the frequency of mature naive-
derived BCRs that displayed polyreactivity and secondly
by determining the frequency of these cells that displayed
autoreactivity toward a human epithelial type 2 (HEp-2)
cell lysate. The median fraction of polyreactive mature
naive-derived BCRs in the healthy controls was 11.7%,
while in the AChR and MuSK MG patients the fraction
was 30.0% and 27.1% respectively (Fig. 2A, 2B and
Fig. S2). These values were statistically different
(P = 0.029).
Using the HEp-2 cell lysate ELISA, we found that the
median fraction of autoreactive mature naive-derived
BCRs in the healthy controls, AChR and MuSK MG
patients were 23.2%, 52.9% and 62.0% respectively
(Fig. 3A and B). Although trending toward significance,
the variance between the groups did not reach statistical
significance (P = 0.10). Collectively, in the two healthy
control donors, where peripheral B cell tolerance is
established normally, the mean fraction of HEp-2-reac-
tive mature naive-derived BCRs was 23.2%  5.9. In all
five MG patients the mean fraction of HEp-2-reactive
mature naive-derived BCRs was 56.2%  11.0. These
respective values, along with those acquired from the
polyreactivity assay, are in agreement with those
reported for both healthy individuals and individuals
with autoimmune diseases that include well-character-
ized peripheral tolerance abnormalities.11,24–26 Thus, our
findings suggest that AChR and MuSK MG patients fail
to remove autoreactive B cells between the new emi-
grant/transitional and mature naive B cell stages, reveal-
ing a second dysfunctional tolerance mechanism in the
periphery.
Reactivity toward MG autoantigens
Given that we demonstrated that the mature naive B cell
repertoire in MG is shaped by defective tolerance
Figure 1. The fidelity of the central tolerance checkpoint is
compromised in patients with MG. The integrity of the central B cell
tolerance checkpoint was examined through quantifying the fraction
of new emigrant/transitional B cells that are polyreactive.
Recombinant antibodies, representing the B cell receptors (BCR), were
generated from single new emigrant/transitional (CD19+CD21loCD10+
IgMhiCD27) B cells derived from three AChR MG patients (MG-
AChR-1, MG-AChR-2, MG-AChR-3), two MuSK MG patients (MG-
MuSK-1, MG-MuSK-2) and two healthy controls (HD-1 and HD-2).
The antibodies were then tested for reactivity with a set of three
structurally distinct antigens: dsDNA, lipopolysaccharide (LPS) and
insulin by ELISA. The antibodies were tested at 1.0 lg/mL and three
additional four-fold serial dilutions (all shown in Fig. S1). The
consolidated three-dimensional plots (A) summarize the reactivity of
each antibody (at the highest concentration of 1.0 lg/mL) from the
subjects toward each antigen in the ELISA. The absorbance values for
LPS (y-axis), dsDNA (x-axis) and insulin (data point size) are plotted
together. Green symbols indicate antibodies that were positive for
binding all three antigens. The values shown in the top left corner of
each graph indicate the fraction of antibodies that were polyreactive.
The mean fraction of polyreactive antibodies was plotted (B) for each
of the three subject groups; HD and two MG disease subtypes (AChR
and MuSK). Statistical differences are shown when significant.
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checkpoints we reasoned that the polyreactive and/or
autoreactive BCRs in this compartment might display
reactivity toward MG-specific autoantigens. We tested the
mature naive-derived BCRs for binding to AChR or
MuSK using a radioimmunoassay and by using a more
sensitive cell-based assay approach. No binding to AChR
or MuSK was detected with either assay format (Fig. S3).
Discussion
Mechanisms of autoimmunity in MG
The two major autoantibody specificities in MG, AChR
and MuSK are demonstrably pathogenic as they affect the
disease by targeting the AChR and disturbing signal trans-
duction at the neuromuscular junction. Both active and
passive transfer of AChR antibodies from humans affect
the disease, demonstrating the direct role these molecules
play in its pathology.2,27–29 Although their production has
been well delineated at a descriptive level, the mechanism
underlying the production of MG autoantibodies remains
unknown. These fundamental aspects of autoimmune
pathology represent considerable gaps in our knowledge
that need to be addressed by further defining the mecha-
nisms contributing to MG immunopathology.
Understanding the fidelity of B cell tolerance represents
one such fundamental aspect of autoimmunity that has
been unexplored in this prototypical autoimmune disease.
We applied a well-established assay platform to measure
the frequency of autoreactive BCRs in the naive repertoire.
In all AChR and MuSK MG patients examined in this study
the frequency of new emigrant/transitional B cells and
mature naive B cells that expressed polyreactive and/or
autoreactive BCRs was significantly increased over normal
controls, revealing both defective central and peripheral
tolerance mechanisms. The frequency of polyreactive new
emigrant BCRs in our MuSK MG patients was conspicu-
ously higher than that in our AChR cohort. These data are
not likely to reflect a quantitative difference in the central
tolerance checkpoint defect we found in both cohorts.
Rather, we reason that this represents natural variability
among our subjects to the antigens used in this assay. Such
variability has been previously observed in subjects with
clearly identifiable defective tolerance checkpoints.12–14
Counter-selection of polyreactive and autoreactive
developing B cells is not absolute in healthy individuals.11
Both polyreactivity and autoreactivity was measured in
BCRs derived from our healthy control cohort, consistent
with other reports.12–14 The occurrence of these low affin-
ity, polyreactive and autoreactive B cells in the healthy
naive repertoire is thought to indicate an overlap between
autoreactive and protective repertoires. The purpose of
which is to provide protection through the production of
natural antibodies and/or provides an initial response to
newly encountered pathogens.30
Our analysis of the BCR immunogenetics data (not
shown) did not reveal sequence characteristics that have
Figure 2. The fidelity of the peripheral tolerance checkpoint is
compromised in patients with MG. The integrity of the peripheral B
cell tolerance checkpoint was examined through quantifying the
fraction of mature naive B cells that are polyreactive or autoreactive.
Recombinant antibodies, representing the BCR, were generated from
single mature naive B cells (CD19+CD21+CD10IgM+CD27) derived
from three AChR MG patients (MG-AChR-1, MG-AChR-2, MG-AChR-
3), two MuSK MG patients (MG-MuSK-1, MG-MuSK-2) and two
healthy controls (HD-1 and HD-2). The antibodies were then tested by
ELISA for polyreactivity with a set of three structurally distinct
antigens: dsDNA, lipopolysaccharide (LPS) and insulin or for
autoreactivity with a HEp-2 cell lysate. The consolidated three-
dimensional plots (A) summarize the reactivity of each antibody (at
the highest concentration of 1.0 lg/mL) from the subjects toward
each antigen in the ELISA. The absorbance values for LPS (y-axis),
dsDNA (x-axis) and insulin (data point size) are plotted together.
Green symbols indicate antibodies that were positive for binding all
three antigens. The values shown in the top left corner of each graph
indicate the frequency (%) of polyreactive antibodies. The mean
fraction of polyreactive (B) antibodies was plotted for each of the
three subject groups; HD and two MG disease subtypes (AChR and
MuSK). Statistical differences are shown when significant. BCR, B cell
receptors.
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been associated with polyspecificity and autoreactivity.
These characteristics included variable region gene seg-
ment usage, D gene reading frame preference and heavy
chain CDR3 features including charge, hydrophobicity
and length. Our data however, do not contradict previous
studies that report detectable differences in these features
between subjects where tolerance is normally and abnor-
mally established. Rather, the absence of measurable dif-
ferences may be due to the limited size of our sequence
library. However, unique BCR repertoire characteristics
are expected to be conspicuous in a B cell compartment
that is shaped without proper tolerance regulation. Next-
generation sequencing (NGS) of the B cell repertoire,
where unrestricted sequence depth can be achieved, is
well suited to accurately establish the repertoire character-
istics that associate with tolerance defects and thus should
be applied in future studies.
MG is a complex and heterogeneous disease. One limi-
tation of our study was that the MG cohort was not
strictly homogeneous in terms of clinical demographics.
Indeed, a considerably larger study would be required to
evaluate the contribution of B cell tolerance defects to
disease subsets. We leave open the possibility that differ-
ences in such defects may associate with MG clinical sub-
types and that our data may not represent MG disease
subtypes not included in our study. However, our data
A
B
Figure 3. The fidelity of the peripheral tolerance checkpoint is compromised in patients with MG: Peripheral tolerance checkpoint HEp-2 ELISAs.
Recombinant antibodies, representing the B cell receptors (BCR), from single mature naive B cells (CD19+CD21+CD10IgM+CD27) derived from
three AChR MG patients (MG-AChR-1, MG-AChR-2, MG-AChR-3) and two MuSK MG patients (MG-MuSK-1, MG-MuSK-2) were cloned,
expressed and then tested for reactivity against a HEp-2 cell lysate by ELISA (A). Dotted lines show the positive control, a monoclonal antibody
(ED38) cloned from a VpreB+L+ peripheral B cell that is highly poly- and self-reactive. Solid lines show the binding curve of each cloned
recombinant antibody. Horizontal lines at 0.5 OD mark the cutoff for positive reactivity. The control group includes antibodies from two healthy
individuals (HD-1, HD-2). For each individual subject the fraction (%) of self-reactive mature naive-derived BCRs is summarized in the pie charts
with the total number of tested clones in the center. Black shading indicates the frequency (%) of HEp-2 antibodies and white shading indicates
the frequency (%) of non-HEp-2 reactive antibodies. The mean fraction of HEp-2-reactive (B) antibodies was plotted for each of the three subject
groups; HD and two MG disease subtypes (AChR and MuSK). Statistical differences are shown when significant.
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demonstrate that the immune dysregulation in the AChR
and MuSK MG patients we studied includes the accumu-
lation of autoreactive BCRs in the naive repertoire, as a
consequence of compromised fidelity in tolerance check-
points. This suggests that defective B cell tolerance may
be a fundamental feature of the disease. Further highlight-
ing this point is that our cohort included patients with
recent diagnosis along with those who had long-standing
disease. How this immune dysregulation contributes to
mechanisms of MG pathology is not evident. Specifically,
it is not clear whether the pool of poly- and auto-reactive
B cells that populate the naive compartment serve as a
reservoir supplying the mature population of B lineage
cells that produce disease associated MG autoantibodies.
Our data showing the lack of specificity toward MG
autoantigens by the self-reactive BCRs prohibited us from
establishing a direct link between the self-reactive naive
repertoire and the development of MG autoantibodies.
We reason that such a link is likely to exist, but the rarity
of antigen-specific B cells, especially those in the naive
compartment with expected lower affinity, prohibits their
easy identification. While our data may suggest that toler-
ance checkpoint defects in MG may be independent of
specific antibody production, we favor a model that
includes poly- and/or autoreactive naive B cells serving as
precursors to mature pathogenic autoantibody-producers.
Contributors to MG tolerance defects
While the development of antibodies that target self in
MG point toward a breach in tolerance, the pre-germinal
center mechanisms underpinning this inability to properly
regulate autoimmunity have not been formally demon-
strated. Our data indicate that tolerance dysfunction pre-
cedes the development of autoimmunity that may occur
during antigen-driven affinity maturation. This supports
the notion that autoreactivity in MG develops prior to
disease manifestation. While this fundamental incapability
to establish B cell tolerance may manifest in the develop-
ment of MG autoantibodies that target AChR or MuSK,
other manifestations are apparent. The first is that MG
can simultaneously co-exist with other autoimmune dis-
eases known to include tolerance defects. The frequency
of a second autoimmune disease occurring in AChR MG
patients is reported to be 13–22%.31 The most frequently
associated autoimmune disease is autoimmune thyroid
disease followed by SLE and RA. The second is that some
patients with non-thymomatous MG harbor autoantibody
specificities, in addition to AChR, that are directed
toward a number of muscle components, including low-
density lipoprotein receptor-related protein 4 (LRP4),32
titin, the ryanodine receptor (RyR)33 and cortactin.34
Given that comorbidities in MG include autoimmune
diseases mediated, in part, by autoantibodies and that
autoantibodies in addition to AChR and MuSK are pre-
sent in MG, collectively point toward a failure to establish
B cell tolerance to self. Thus, the loss of tolerance in MG
may manifest immunologically through the production of
several autoantibody specificities, while the AChR and
MuSK autoantibodies result in the clinical manifestation
of the disease.
Distinct mechanisms contribute to B cell selection at
each checkpoint. Central tolerance is associated with
intrinsic BCR and toll-like receptor (TLR) signals,35 while
extrinsic signals, delivered by Tregs, are essential for the
establishment and for the maintenance of peripheral tol-
erance.36 Thus, an additional factor influencing tolerance
checkpoint defects may be linked to MG: Defects in the
ability of Tregs to suppress responder cells. Tregs derived
directly from the thymus of patients with MG are present
at normal frequencies, but their ability to suppress is
defective37 and T responders also derived from MG thy-
mus resist Treg mediated-suppression.38 In the periphery,
Treg-mediated suppression of responder T cells is
impaired in MG patients, but can be restored using Tregs
isolated from healthy controls.39
Immune dysregulation in AChR and MuSK
MG
This study included both AChR and MuSK MG. Our
cohort of patients from both disease subtypes included
compromised B cell tolerance checkpoint integrity, indi-
cating that they share a common immune dysregulation.
This is intriguing given how dissimilarly the autoanti-
body-mediated pathology propagates in the respective
subtypes. In AChR MG the autoantibodies are primarily
of the IgG1 and IgG3 subclass,4,40 both of which are asso-
ciated with Th1 responses. These IgGs are thought to tar-
get the receptor through antigenic modulation by
crosslinking AChR molecules, complement activation and
functional AChR blockage.40–44 The pathogenic autoanti-
bodies that recognize MuSK are mainly of the IgG4 sub-
class,45 which are associated with a Th2 response. This
subclass is inefficient at fixing complement and directing
antibody-dependent cell-mediated cytotoxicity (ADCC).
Rather, MuSK IgG4 antibodies disrupt agrin-stimulated
MuSK signaling by inhibiting the association between
LRP4 and MuSK.46 Furthermore, serum-derived IgG4,
but not IgG1-3, transfer from MuSK patients induced
severe muscle weakness in mice indicating that MuSK
IgG4 autoantibodies are directly pathogenic.45 It is now
understood that IgG4 recombines half-antibodies with
other IgG4 antibodies (“Fab arm-exchange”) generating
hetero-bi-specific antibodies. These IgG4 become func-
tionally monovalent and, accordingly, are unable to cross-
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link antigens.47 Fab arm-exchange has been demonstrated
in experimental MuSK MG.48 A phenomenon such as Fab
arm-exchange, which occurs independently of immune
cell influence, might suggest that MuSK MG could arise
in the absence of a dysregulated cellular immune system.
That is, hetero bi-specificity could represent a mechanism
of autoreactivity that is causatively exclusive of other
autoimmune mechanisms. However, our study suggests
that MuSK MG also includes a more fundamental
immune dysregulation that occurs upstream of antibody
production and thereby implies that a number of ele-
ments are likely to contribute to the disease pathology.
Treatment strategies that contend with
intrinsic tolerance defects
The current standard treatment for MG consists of
symptomatic therapy with acetylcholinesterase inhibit-
ors and generalized immunomodulatory agents such as
corticosteroids, cyclosporin and azathioprine, intravenous
immunoglobulin as well as thymectomy and plasma-
pheresis.49,50 Two of our patients had received low dose
corticosteroids, but still had remarkably high frequencies
of polyreactive and autoreactive BCRs. This suggests that
steroid treatment is unlikely to alter B cell tolerance
defects and further suggests that such defects represent
fundamental aspects of autoimmunity. This point of
view is supported by recent studies demonstrating that
neither B cell depletion nor methotrexate and/or anti-
TNFa therapy corrects the elevated frequencies of
polyreactive and autoreactive BCRs, which persist after
such treatment.16,51
In response to the need for more effective treatment,
biologics have been applied to MG management. Several
recent studies8,9 have demonstrated the benefits of ritux-
imab-mediated B cell depletion in refractory MG, espe-
cially in MuSK MG. Rituximab led to a sustained clinical
improvement in parallel to a reduction or discontinuation
of corticosteroid therapy and plasma exchange treatments.
The observed positive effect of rituximab in patients with
MG is promising and suggests that further investigation
of this agent in MG is warranted; both in terms of a clini-
cal trial and in understanding how it interrupts the
autoimmune mechanisms. Our study highlights conceiv-
able associations between the autoimmune mechanisms of
MG and B cell depletion. Particularly, the durability of B
cell depletion in MG may be fragile given that the repopu-
lated naive repertoire is expected to carry the intrinsic
defects that contribute to tolerance checkpoint breaches.51
This is highlighted in the case of AChR MG where the
patient response is usually weaker and short lasting, despite
improvement shortly after rituximab treatment. Although
the extraordinary and long-lasting response to rituximab of
MuSK MG is encouraging, the benefit may not be perma-
nent given the breach in B cell tolerance fidelity.
Conclusion and future perspectives
There is strong evidence that MuSK and AChR MG are dis-
tinct disease entities with different etiological and patholog-
ical mechanisms. Our study revealed defective central and
peripheral tolerance mechanisms in both MG subgroups.
These defective central and peripheral tolerance checkpoints
in MG may indirectly contribute to the accumulation of
autoreactive antibodies through serving as precursors for
autoantibody-producing B cells. Understanding the exact
pathological mechanisms that account for autoantibody
production and identifying additional elements that are
involved in tolerance mechanisms are the next steps toward
developing durable B cell targeted therapies for MG.
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Figure S1. The fidelity of the central tolerance checkpoint
is compromised in patients with MG: Central tolerance
checkpoint polyreactivity ELISAs. The BCR from single
new emigrant/transitional B cells (CD19 + CD21loCD10
+ IgMhiCD27–) derived from three AChR MG patients
(MGAChR-1, MG-AChR-2, MG-AChR-3) and two MuSK
MG patients (MG-MuSK-1, MG-MuSK-2) were cloned,
expressed as recombinant antibodies and then tested for
reactivity against dsDNA, insulin and LPS by ELISA. Dot-
ted lines show the positive control, a monoclonal anti-
body (ED38) cloned from a VpreB+L+ peripheral B cell
that is highly poly- and self-reactive. Solid lines show the
binding curve of each cloned recombinant antibody. Hor-
izontal lines at 0.5 OD405 nm marks the cut-off for posi-
tive reactivity. Negative control group includes antibodies
from two healthy individuals (HD-1, HD-2). For each
individual subject the proportion of polyreactive and
non-polyreactive new emigrant B cells is summarized in
the pie charts with the total number of tested clones in
the center. Black shading indicates the frequency (%) of
polyreactive antibodies and white shading indicates the
frequency (%) of non-polyreactive antibodies.
Figure S2. The fidelity of the peripheral tolerance check-
point is compromised in patients with MG: Peripheral
tolerance checkpoint polyreactivity ELISAs. The BCR
from single mature naive B cells (CD19 + CD21 + CD10–
IgM+CD27–) derived from three AChR MG patients
(MG-AChR-1, MGAChR- 2, MG-AChR-3) and MuSK
MG patients (MG-MuSK-1, MG-MuSK-2) were cloned,
expressed as recombinant antibodies and then tested for
reactivity against dsDNA, insulin and LPS by ELISA. Dot-
ted lines show the positive control, a monoclonal anti-
body (ED38) cloned from a VpreB+L+ peripheral B cell
that is highly poly- and self-reactive. Solid lines show the
binding curve of each cloned recombinant antibody. Hor-
izontal lines at 0.5 marks the cut off OD405 nm for posi-
tive reactivity. The control group includes antibodies
from two healthy individuals (HD-1, HD-2). For each
individual subject the frequency (%) of polyreactive and
non-polyreactive mature naive B cells is summarized in
the pie charts with the total number of tested clones in
the center. Black shading indicates the frequency (%) of
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polyreactive antibodies and white shading indicates the
frequency (%) of non-polyreactive antibodies.
Figure S3. Mature naive B cell-derived BCRs reactivity
toward AChR and MuSK. The BCR from single mature
naive B cells (CD19 + CD21 + CD10–IgM+CD27–)
derived from three AChR MG patients (MG-AChR-1,
MG-AChR-2, MG-AChR-3), two MuSK MG patients
(MGMuSK-1, MG-MuSK-2) and two healthy individuals
(HD-1, HD-2) were cloned, expressed as recombinant
antibodies (rIgG) and then tested for reactivity against
AChR or MuSK. A radioimmunoassay (RIA) was first
used to evaluate the specificity of the rIgG to AChR (A)
or MuSK (B). Recombinant antibody (2.5 lg) was diluted
to 50 lL in Hartmann’s solution and mixed with 1 lL
normal human serum and 50 ll of radioactive antigen
(either AChR or MuSK from RSR Ltd). These mixtures
were incubated overnight at 4°C. Polyreactive goat anti-
human Ig (25 lL) was incubated with the mix for 1 h to
allow precipitation. The pellet was centrifuged and
washed twice and counted on an automatic gamma coun-
ter. Cell-based assays (CBA) were used further evaluate
the same recombinant antibodies using transfected human
embryonic kidney (HEK) 293T
Table S1. Single cell PCR efficiency.
Table S2. Sequence and reactivity tables for the MG and
HD study subjects.
454 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Defective B-Cell Tolerance in Myasthenia Gravis. J.Y. Lee et al.
